ES2671932T3 - Tratamiento de hipertensión arterial pulmonar con células madre mesenquimatosas - Google Patents

Tratamiento de hipertensión arterial pulmonar con células madre mesenquimatosas Download PDF

Info

Publication number
ES2671932T3
ES2671932T3 ES13825764.7T ES13825764T ES2671932T3 ES 2671932 T3 ES2671932 T3 ES 2671932T3 ES 13825764 T ES13825764 T ES 13825764T ES 2671932 T3 ES2671932 T3 ES 2671932T3
Authority
ES
Spain
Prior art keywords
cells
cell
mesenchymal stem
pharmaceutical composition
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13825764.7T
Other languages
English (en)
Spanish (es)
Inventor
Roger Jeffs
Thomas Petersen
Roger M. Ilagan
Michael Wade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Therapeutics Corp
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Application granted granted Critical
Publication of ES2671932T3 publication Critical patent/ES2671932T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES13825764.7T 2012-08-01 2013-07-30 Tratamiento de hipertensión arterial pulmonar con células madre mesenquimatosas Active ES2671932T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261678207P 2012-08-01 2012-08-01
US201261678207P 2012-08-01
US201361750458P 2013-01-09 2013-01-09
US201361750458P 2013-01-09
PCT/US2013/052695 WO2014022373A1 (en) 2012-08-01 2013-07-30 Treatment of pulmonary arterial hypertension with mesenchymal stem cells

Publications (1)

Publication Number Publication Date
ES2671932T3 true ES2671932T3 (es) 2018-06-11

Family

ID=50028470

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13825764.7T Active ES2671932T3 (es) 2012-08-01 2013-07-30 Tratamiento de hipertensión arterial pulmonar con células madre mesenquimatosas

Country Status (11)

Country Link
US (2) US10071123B2 (enExample)
EP (1) EP2879682B1 (enExample)
JP (2) JP6901823B2 (enExample)
KR (1) KR102143255B1 (enExample)
CN (2) CN111803523A (enExample)
AU (2) AU2013296611B2 (enExample)
CA (1) CA2880808C (enExample)
ES (1) ES2671932T3 (enExample)
IL (1) IL237021B (enExample)
IN (1) IN2015DN00934A (enExample)
WO (1) WO2014022373A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102143961B1 (ko) 2012-08-01 2020-08-12 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린-처리된 내피 전구 세포를 사용한 폐동맥 고혈압의 치료
EP3556850A1 (en) * 2012-12-12 2019-10-23 Mesoblast, Inc. Treatment of diseases of endothelial dysfunction and inflammation
WO2014110094A1 (en) * 2013-01-09 2014-07-17 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP2943479B1 (en) 2013-01-11 2020-04-15 Corsair Pharma, Inc. Prodrugs of treprostinil
DK3060041T3 (da) 2013-10-25 2021-03-22 Insmed Inc Prostacyclinforbindelser
CA2967385C (en) 2014-11-18 2023-05-16 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
IL262720B2 (en) 2016-05-05 2024-06-01 Liquidia Tech Inc Dry powder treprostinil for the treatment of pulmonary hypertension
JP2019518049A (ja) * 2016-06-17 2019-06-27 ユナイテッド セラピューティクス コーポレイション 高い効能を有する細胞外小胞
US10946047B2 (en) 2016-06-17 2021-03-16 United Therapeutics Corporation Extracellular vesicles with enhanced potency
WO2018080990A1 (en) * 2016-10-24 2018-05-03 United Therapeutics Corporation Enhancement of msc immunomodulatory properties by treprostinil
WO2018119185A1 (en) * 2016-12-23 2018-06-28 StemBios Technologies, Inc. Use of somatic stem cells for increasing heme oxygenase level
US11911349B2 (en) 2018-03-30 2024-02-27 Nattopharma As Rapidly improving vascular conditions by administering vitamin K
IL281867B2 (en) 2018-10-05 2024-07-01 Xenotherapeutics Inc Xenotransplantation products and methods
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
EP3962472A4 (en) 2019-04-29 2023-01-25 Insmed Incorporated DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF
EP4285915A1 (en) * 2022-06-03 2023-12-06 Medizinische Hochschule Hannover Human mesenchymal stem cell-conditioned medium for use in treatment of chronic heart-lung and vascular diseases, in particular, of pulmonary arterial hypertension (pah)

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089815A (en) 1951-10-11 1963-05-14 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US5026365A (en) 1987-04-29 1991-06-25 The University Of Massachusetts Method and apparatus for therapeutically treating immunological disorders and disease states
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
EP0317156B2 (en) 1987-11-09 1997-11-12 Becton, Dickinson and Company Method for analysis of hematopoietic cells in a sample
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5071741A (en) 1988-04-18 1991-12-10 Cryolife, Inc. Cryoprotective agent and its use in cryopreservation of cellular matter
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
HK1001832A1 (en) 1991-04-25 1998-07-10 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
IL104470A0 (en) 1992-01-21 1993-05-13 Cryopharm Corp Process for freezing cells and cell like materials and compositions prepared thereby
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
EP1179350A3 (en) 1993-08-12 2003-01-02 Cytotherapeutics, Inc. Encapsulated cell system for implantation into the human CNS
US5518878A (en) 1993-09-15 1996-05-21 Organogenesis Inc. Cryopreservation of cultured skin or cornea equivalents with agitation
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
DE69530914T2 (de) 1994-02-17 2004-03-11 New York Blood Center, Inc. Biologische bioadhäsive präparate, die fibrinkleber und liposomen enthalten, verfahren für ihre herstellung und verwendung
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5580714A (en) 1995-03-08 1996-12-03 Celox Laboratories, Inc. Cryopreservation solution
US5629145A (en) 1995-03-24 1997-05-13 Organ, Inc. Cryopreservation of cell suspensions
US5643192A (en) 1995-04-06 1997-07-01 Hamilton Civic Hospitals Research Development, Inc. Autologous fibrin glue and methods for its preparation and use
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
CA2238434A1 (en) 1995-12-15 1997-06-19 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
WO1998014058A1 (en) 1996-10-03 1998-04-09 The Regents Of The University Of California Cryopreservation of human adult and fetal pancreatic cells and human platelets
WO1998020027A2 (en) 1996-11-01 1998-05-14 Eurogene Limited Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device
DK1007631T4 (da) 1997-07-14 2009-04-27 Osiris Therapeutics Inc Hjertemuskelregeneration ved anvendelse af mesenkymale stamceller
US9585916B2 (en) * 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
US20030118567A1 (en) 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US9320829B2 (en) 2000-03-15 2016-04-26 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
JP2004513676A (ja) 2000-06-22 2004-05-13 オースティン，サム，エル 生体接着剤組成物及びその製造と使用
WO2004050180A2 (en) 2002-11-30 2004-06-17 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
JP5190200B2 (ja) * 2003-12-16 2013-04-24 ユナイテッド セラピューティクス コーポレイション 虚血性病変の治療および予防のためのトレプロスチニルの用途
KR101536613B1 (ko) 2004-09-24 2015-07-14 메소블라스트, 아이엔씨. 증폭된 다능성 간엽 전구세포 자손 및 이의 용도
CA3022238A1 (en) 2005-08-19 2007-02-22 Duke University Stem cell derived factors for treating pathologic conditions
US20070065414A1 (en) 2005-09-16 2007-03-22 Boston Scientific Scimed, Inc. Enhanced delivery of cells
AU2006325710B2 (en) * 2005-12-16 2012-05-17 Ethicon, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US8652201B2 (en) 2006-04-26 2014-02-18 The Cleveland Clinic Foundation Apparatus and method for treating cardiovascular diseases
CA2705450A1 (en) * 2006-04-27 2007-11-08 Cell Therapy Technologies, Inc. Et Al Stem cells for treating lung diseases
WO2008077094A2 (en) * 2006-12-19 2008-06-26 Children's Medical Center Corporation Methods for promoting neovascularization
EP2120977B1 (en) * 2007-02-12 2013-05-15 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
JP2011015609A (ja) 2007-10-30 2011-01-27 Asahikawa Medical College 内皮前駆細胞（ｅｐｃ）の増殖・分化誘導方法
PT2254586E (pt) 2008-02-22 2015-05-18 Agency Science Tech & Res Partículas de células estaminais mesenquimais
EP2608797B1 (en) 2010-08-27 2015-09-23 University of Miami Bone marrow derived cd271 precursor cells for cardiac repair
CN103379907B (zh) 2011-01-13 2018-01-09 塞法姆公司 增强造血干细胞移入的方法
EP3269802B1 (en) * 2011-09-30 2019-10-23 Bluebird Bio, Inc. Compounds for improved viral transduction
KR102143961B1 (ko) 2012-08-01 2020-08-12 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린-처리된 내피 전구 세포를 사용한 폐동맥 고혈압의 치료
WO2014110094A1 (en) 2013-01-09 2014-07-17 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

Also Published As

Publication number Publication date
AU2013296611B2 (en) 2017-11-23
CA2880808A1 (en) 2014-02-06
US20150246078A1 (en) 2015-09-03
US10071123B2 (en) 2018-09-11
EP2879682B1 (en) 2018-03-21
US20190008904A1 (en) 2019-01-10
CN104684561A (zh) 2015-06-03
JP2019123726A (ja) 2019-07-25
AU2018201231B2 (en) 2019-12-05
KR20150038162A (ko) 2015-04-08
CN111803523A (zh) 2020-10-23
KR102143255B1 (ko) 2020-08-10
CA2880808C (en) 2023-01-24
AU2013296611A1 (en) 2015-03-05
AU2018201231A1 (en) 2018-03-15
US11666602B2 (en) 2023-06-06
JP6901823B2 (ja) 2021-07-14
WO2014022373A1 (en) 2014-02-06
EP2879682A1 (en) 2015-06-10
IL237021B (en) 2018-02-28
EP2879682A4 (en) 2016-03-16
JP2015524437A (ja) 2015-08-24
IN2015DN00934A (enExample) 2015-06-12

Similar Documents

Publication Publication Date Title
ES2671932T3 (es) Tratamiento de hipertensión arterial pulmonar con células madre mesenquimatosas
ES2888909T3 (es) Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas
ES2869701T3 (es) Tratamiento de hipertensión arterial pulmonar con células progenitoras endoteliales tratadas con prostaciclina